|
|
 | | | |
- close
- close
- close
- close
Eli Lilly and Company (LLY) |
Wall Street Journal
Jun 18
Comment
Federal regulators are investigating the death of two people who received an injection of an Eli Lilly antipsychotic drug.
StreetInsider.com
Jun 18
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Dividends/Eli+Lilly+%26+Co.+%28LLY%29+Declares+%240.49+Quarterly+Dividend%3B+3.8%25+Yield/8426855.html for the full story.
Market Intelligence Center
Jun 18
Comment
Eli Lilly and Co (NYSE: LLY) closed Monday's trading session at $52.36. In the past year, the stock has hit a 52-week low of $41.41 and 52-week high of $58.41. Eli Lilly (LLY) stock has been showing support around $51.69 and resistance in the...
FierceBiotech
Jun 17
Comment
Eli Lilly is stepping in to take control of an experimental diabetes drug from Canada's Transition Therapeutics, paying $7 million upfront and promising up to $240 million in milestones. The drug--TT-401--is headed into Phase II. Transition will...
Forbes
Jun 14
Comment
Once again, Eli Lilly has suffered a setback trying to find a useful drug to combat Alzheimer’s. Last year, a pair of late-stage trials for an injectable drug called solanezumab failed to meet primary endpoints in patients with mild-to-moderate...
FierceBiotech
Jun 13
Comment
In yet another indication of the yawning gap between what drug developers know about Alzheimer's and how it could be treated, Eli Lilly today decided to scrap its Phase II study for a BACE inhibitor after gathering abnormal liver tests from patients.
StreetInsider.com
Jun 13
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Lilly+and+Co.+%28LLY%29+Ceases+BACE+Phase+II+Voluntarily%3B+Sees+Immaterial+Charge/8415785.html for the full story.
MedPage Today
Jun 13
Comment
(MedPage Today) -- Two genes may predict which women would benefit from breast cancer primary prevention with tamoxifen or raloxifene (Evista), analysis of the pivotal trials showed.
FierceBiotech
Jun 13
Comment
Efficacy results for an experimental rheumatoid arthritis drug in development by Eli Lilly and Incyte held up well as patients in a Phase IIb trial were tracked over the course of a full year.
Market Intelligence Center
Jun 12
Comment
Eli Lilly and Co (NYSE: LLY) closed Tuesday's trading session at $51.94. In the past year, the stock has hit a 52-week low of $41.31 and 52-week high of $58.41. Eli Lilly (LLY) stock has been showing support around $51.47 and resistance in the...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
| |||||||
